Evolve Business Intelligence released a new market research report on Global IPV Vaccines Market by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX and POLYMILEX), by Distribution Channel (Private and Public) and by Geography – COVID -19 Impact Analysis , Post-COVID Analysis, Opportunities, Trends and Forecasts from 2022 to 2032

The market size for IPV vaccines is projected to grow at a CAGR of approximately 10% from 2022 to 2032. The biggest factor driving the growth of the IPV vaccines market is the increasing prevalence of infectious diseases. One of the key market drivers for the IPV vaccine market is the increasing emphasis on preventive healthcare. With growing awareness of the cause and effect of the mass spread of infectious diseases, the focus has shifted from treating these diseases to preventing them. The focus is on mass immunization, which has led to the development of multiple vaccines to prevent the spread of the diseases.

Request a free sample report or PDF copy: https://report.evolvebi.com/index.php/sample/request?referer=parity&reportCode=015664

key figures
The IPV Vaccines market report provides detailed information about the company and its performance to date. This will give you a clear picture of how strong an industry is, what kind of wealth comes with it, and which areas are growing over time. Every single element in a market report is updated regularly to help us read the market better. The report also includes general risks associated with marketing in such a delicate industry as it offers advice for future planning of a related business expansion.

The key players profiled in the report are:
• GlaxoSmithKline Plc
• Sanofi SA
• Serum Institute of India Pvt. GmbH.
• PT Bio Farma
• AJ vaccines

Today’s business environment is competitive and challenging, which means companies need to keep up with new technologies and seek market opportunities. Our recent research on global IPV…